X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9245) 9245
Book Review (1735) 1735
Publication (501) 501
Book Chapter (157) 157
Conference Proceeding (130) 130
Dissertation (122) 122
Book / eBook (9) 9
Web Resource (6) 6
Magazine Article (3) 3
Data Set (2) 2
Government Document (2) 2
Paper (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6809) 6809
humans (4598) 4598
pharmacology & pharmacy (3432) 3432
drug interactions (3417) 3417
drug-drug interactions (2909) 2909
animals (2649) 2649
male (2299) 2299
drug-drug interaction (2163) 2163
pharmacokinetics (1546) 1546
female (1498) 1498
rats (1083) 1083
receptors, drug - drug effects (1039) 1039
adult (987) 987
middle aged (879) 879
metabolism (822) 822
in-vitro (705) 705
aged (650) 650
pharmacology (617) 617
dose-response relationship, drug (593) 593
analysis (570) 570
inhibition (563) 563
drug–drug interaction (560) 560
mice (543) 543
drugs (515) 515
toxicology (491) 491
kinetics (486) 486
drug–drug interactions (474) 474
p-glycoprotein (471) 471
cytochrome p450 (431) 431
biochemistry & molecular biology (416) 416
in vitro techniques (413) 413
cytochrome p-450 enzyme system - metabolism (403) 403
cytochrome p-450 (397) 397
drug interaction (395) 395
young adult (379) 379
area under curve (375) 375
drug therapy, combination (366) 366
models, biological (360) 360
research (344) 344
pharmacology/toxicology (342) 342
chemistry, multidisciplinary (333) 333
drug therapy (331) 331
enzymes (328) 328
liver (324) 324
human liver-microsomes (314) 314
receptors, drug - metabolism (309) 309
adolescent (299) 299
rats, sprague-dawley (298) 298
prediction (286) 286
administration, oral (280) 280
time factors (268) 268
cytochrome p-450 cyp3a - metabolism (266) 266
pharmacy (265) 265
therapy (264) 264
metabolites (263) 263
liver - metabolism (261) 261
cells, cultured (256) 256
chemistry, medicinal (255) 255
cancer (252) 252
polypharmacy (252) 252
pharmaceutical preparations - metabolism (247) 247
cross-over studies (245) 245
physiological aspects (242) 242
complications and side effects (237) 237
microsomes, liver - metabolism (237) 237
cyp3a4 (236) 236
pharmacodynamics (233) 233
medicine & public health (230) 230
aged, 80 and over (228) 228
drug design (228) 228
protein binding (228) 228
oncology (226) 226
biomedicine (220) 220
enzyme inhibitors - pharmacology (219) 219
safety (217) 217
internal medicine (214) 214
microsomes, liver - enzymology (211) 211
expression (210) 210
microsomes, liver - drug effects (210) 210
risk factors (210) 210
binding sites (208) 208
drug metabolism (204) 204
drug synergism (200) 200
induction (199) 199
warfarin (191) 191
cell line (188) 188
dosage and administration (188) 188
structure-activity relationship (187) 187
article (186) 186
care and treatment (185) 185
healthy-volunteers (184) 184
rats, wistar (181) 181
risk (179) 179
absorption (177) 177
toxicity (177) 177
hiv (175) 175
proteins (173) 173
binding (172) 172
health aspects (172) 172
hiv infections - drug therapy (171) 171
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6302) 6302
Japanese (1721) 1721
Chinese (1399) 1399
German (63) 63
French (42) 42
Spanish (31) 31
Russian (26) 26
Slovenian (10) 10
Czech (7) 7
Korean (6) 6
Portuguese (6) 6
Polish (5) 5
Italian (4) 4
Hungarian (2) 2
Turkish (2) 2
Bulgarian (1) 1
Dutch (1) 1
Norwegian (1) 1
Slovak (1) 1
Thai (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pharmaceutical Research, ISSN 0724-8741, 5/2008, Volume 25, Issue 5, pp. 1063 - 1074
To assess the consequences of multiple inhibitors and differential inhibition mechanisms on the prediction of 12 gemfibrozil drug–drug interactions (DDIs). In... 
Biomedical Engineering | Biochemistry, general | CYP2C8 | Biomedicine | enzyme inhibition | Pharmacy | drug–drug interactions | Medical Law | Pharmacology/Toxicology | gemfibrozil | OATP1B1 | Enzyme inhibition | Drug-drug interactions | Gemfibrozil | PARALLEL PATHWAYS | CYP3A4 IN-VITRO | HUMAN LIVER-MICROSOMES | TRANSPLANT RECIPIENTS | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | ATORVASTATIN | drug-drug interactions | PHARMACOKINETICS | PLASMA-CONCENTRATIONS | PHARMACOLOGY & PHARMACY | HEALTHY-VOLUNTEERS | CYCLOSPORINE | Cell Line | Cytochrome P-450 CYP2C8 | Hypolipidemic Agents - adverse effects | Predictive Value of Tests | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Area Under Curve | Humans | Immunosuppressive Agents - pharmacokinetics | Enzyme Inhibitors - pharmacology | Gemfibrozil - pharmacokinetics | Gemfibrozil - adverse effects | Aryl Hydrocarbon Hydroxylases - metabolism | Carrier Proteins - metabolism | Drug Interactions | Glucuronides - metabolism | Cyclosporine - adverse effects | Cyclosporine - pharmacokinetics | Immunosuppressive Agents - adverse effects | Kinetics | Hypolipidemic Agents - pharmacokinetics | Databases, Factual | Physiological aspects | Complications and side effects | Analysis | Drug interactions | Low density lipoproteins | Enzymes | Biomedical research | Inhibitor drugs | Predictions | Pharmacology | Models | Metabolism | Index Medicus
Journal Article
Journal Article
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 05/2018, Volume 115, Issue 18, pp. E4304 - E4311
Journal Article
01/2014
Many people have the mistaken notion that, being natural, all herbs and foods are safe; this is not so. Very often, herbs and food may interact with... 
drug–drug interaction | Cytochrome P-450 | herbal–drug interaction | Herbal Preparation | Herbal drug
Web Resource
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 05/2018, Volume 33, Issue 5, pp. 1100 - 1107
Journal Article
Pharmaceutical Research, ISSN 0724-8741, 10/2012, Volume 29, Issue 10, pp. 2860 - 2873
To develop physiologically based pharmacokinetic (PBPK) model to predict the pharmacokinetics and drug-drug interactions (DDI) of pravastatin, using the in... 
Biomedical Engineering | Biochemistry, general | Biomedicine | transporters | Pharmacy | physiologically based pharmacokinetic (PBPK) model | pravastatin | Medical Law | Pharmacology/Toxicology | drug-drug interaction | OATP1B1 | Drug-Drug interaction | Transporters | Physiologically based pharmacokinetic (PBPK) model | Pravastatin | COA REDUCTASE INHIBITORS | INTERINDIVIDUAL DIFFERENCES | HEALTHY-SUBJECTS | TRANSPLANT PATIENTS | HEPATIC-UPTAKE | CHEMISTRY, MULTIDISCIPLINARY | PHYSICOCHEMICAL PROPERTIES | CYCLOSPORINE-A | PHARMACOKINETICS | TISSUE DISTRIBUTION | IN-VIVO | PHARMACOLOGY & PHARMACY | Rifampin - pharmacokinetics | Area Under Curve | Humans | Middle Aged | Male | Hepatocytes - metabolism | Enzyme Inhibitors - administration & dosage | Young Adult | Drug Interactions | Biological Transport | Enzyme Inhibitors - pharmacokinetics | Computer Simulation | Cyclosporine - pharmacokinetics | Adult | Female | Rifampin - administration & dosage | Gemfibrozil - administration & dosage | Pravastatin - pharmacology | Organic Anion Transporters - antagonists & inhibitors | Liver - metabolism | Cells, Cultured | Gemfibrozil - pharmacokinetics | Pravastatin - administration & dosage | Adolescent | Cyclosporine - administration & dosage | Aged | Solute Carrier Organic Anion Transporter Family Member 1b1 | Pravastatin - pharmacokinetics | Pharmacology | Kinetics | Pharmaceutical sciences | Statins | Index Medicus
Journal Article